State Ledger
Company profile

Lexeo Therapeutics, Inc. CIK 1907108

Ticker
LXEO (Nasdaq)
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
New York, NY 10010
Fiscal year end
2025 (FY)
Market Data
Close
$3.05
Change
-$0.16
Change %
-4.98%
Volume
39,927

LXEO · trading date Oct 12, 2026 · previous close $3.21 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$99.96M
Total assets
$268.69M
Total liabilities
$22.02M
Stockholders' equity
$246.67M
Cash & equivalents
$63.00M
Operating income
-$109.26M
Operating cash flow
-$98.56M
Capital expenditures
$397.0K

Fiscal year 2025, via 10-K filed 2026-03-30. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$98.96M
Free cash flow margin
—
Liabilities / assets
8.2%
Equity / assets
91.8%
CapEx / revenue
—
Operating cash flow / net income
0.99×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$99.96M $268.69M $22.02M $246.67M
2024 — -$98.33M $146.94M $30.10M $116.84M
2023 — -$66.39M $139.81M $26.27M $113.54M
2022 $654.0K -$59.28M $97.08M $25.00M -$112.95M
Company Details
SIC code
2836
Active filer
Yes
Most recent SEC filing
Form 4
2026-08-19
Financials filed via
Form 10-K
filed 2026-03-30

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
New York, NY 10010
345 PARK AVENUE SOUTH
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:46 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to New York — Public Companies